欧盟对卫生技术评估的监管：其成功需要具备哪些条件？ - Suppr

Suppr

超能文献

European union regulation of health technology assessment: what is required for it to succeed?

作者信息

Drummond Michael, Tarricone Rosanna, Torbica Aleksandra

机构信息

Centre for Health Economics, University of York, York, UK.

CERGAS, SDA Bocconi School of Management, Milan, Italy.

出版信息

Eur J Health Econ. 2022 Aug;23(6):913-915. doi: 10.1007/s10198-022-01458-6. Epub 2022 Mar 29.

DOI:10.1007/s10198-022-01458-6

PMID:35348920

Abstract

摘要

相似文献

European union regulation of health technology assessment: what is required for it to succeed?欧盟对卫生技术评估的监管：其成功需要具备哪些条件？

Eur J Health Econ. 2022 Aug;23(6):913-915. doi: 10.1007/s10198-022-01458-6. Epub 2022 Mar 29.

Access in all areas? A round up of developments in market access and health technology assessment: part 1.全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。

J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.

IQWiG: an opportunity lost?德国卫生经济与评估研究所（IQWiG）：错失的机遇？

Eur J Health Econ. 2008 Aug;9(3):205-7. doi: 10.1007/s10198-008-0109-2.

Introduction: health technology assessment and the European Union.引言：卫生技术评估与欧盟

Int J Technol Assess Health Care. 2000 Spring;16(2):299-302. doi: 10.1017/s0266462300101011.

Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.提高监管评估报告对健康技术评估的贡献--欧洲药品管理局与欧洲卫生技术评估网络的合作。

Value Health. 2014 Jul;17(5):634-41. doi: 10.1016/j.jval.2014.04.006. Epub 2014 Jun 30.

[Policy developments of health technology assessment in the European Union].[欧盟卫生技术评估的政策发展]

Postepy Biochem. 2019 Nov 29;65(4):319-321. doi: 10.18388/pb.2019_285.

Health technology assessment for pharmaceuticals in the European Union: what lessons after two decades?欧盟药品的卫生技术评估：二十年后有哪些经验教训？

Intern Emerg Med. 2022 Aug;17(5):1251-1253. doi: 10.1007/s11739-022-03008-7. Epub 2022 Jun 8.

Toward a sustainable European Network for Health Technology Assessment. The EUnetHTA project.迈向可持续的欧洲卫生技术评估网络。欧盟卫生技术评估网络（EUnetHTA）项目。

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Mar;49(3):283-5. doi: 10.1007/s00103-005-1229-9.

Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?欧盟药品监管中的卫生技术评估：我们是否需要另一个机构？

J R Soc Med. 2020 Jan;113(1):12-15. doi: 10.1177/0141076819888618. Epub 2019 Nov 15.

[Bioethics: A necessary bridge between scientific and humanist views for the evaluation of healthcare technologies].[生物伦理学：评估医疗技术时科学与人文主义观点之间的必要桥梁]

J Healthc Qual Res. 2019 Jan-Feb;34(1):1-2. doi: 10.1016/j.jhqr.2018.11.002. Epub 2019 Feb 1.

引用本文的文献

Health technology assessment (HTA) and performance management (PM): a scoping review on the intersecting realms.卫生技术评估（HTA）与绩效管理（PM）：关于交叉领域的范围综述

BMC Health Serv Res. 2025 Jul 3;25(1):917. doi: 10.1186/s12913-025-12879-3.

The Art of Bridge Building: A Look at the European-Level Cooperation in HTA (EU-HTA).桥梁建设的艺术：审视卫生技术评估中的欧洲层面合作（欧盟卫生技术评估）

J Mark Access Health Policy. 2025 May 28;13(2):26. doi: 10.3390/jmahp13020026. eCollection 2025 Jun.

ARM's Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead.ARM对首个细胞和基因治疗产品联合临床评估的看法：前行道路上的挑战与机遇

J Mark Access Health Policy. 2025 Apr 3;13(2):14. doi: 10.3390/jmahp13020014. eCollection 2025 Jun.

The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms.真实世界证据在法国、德国、意大利、西班牙和英国卫生技术决策中的作用与价值：关于外部对照臂的见解

Int J Technol Assess Health Care. 2025 Apr 22;41(1):e25. doi: 10.1017/S0266462324004720.

Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges.绘制欧盟联合临床评估与地方卫生技术评估决策之间的方法差距：对部分欧盟市场指南及协调挑战的环境扫描

J Comp Eff Res. 2025 May;14(5):e240240. doi: 10.57264/cer-2024-0240. Epub 2025 Feb 26.

Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy.在欧洲卫生技术评估中避免错误并找到正确平衡：欧洲准入学院产生的见解

J Mark Access Health Policy. 2025 Feb 10;13(1):6. doi: 10.3390/jmahp13010006. eCollection 2025 Mar.

The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?欧盟卫生技术评估法规的光环效应：跨职能团队准备好了吗？

J Mark Access Health Policy. 2025 Jan 30;13(1):3. doi: 10.3390/jmahp13010003. eCollection 2025 Mar.

From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.从愿景到现实：欧盟的药品改革与改善可及性之路。

Pharmacoecon Open. 2025 May;9(3):331-339. doi: 10.1007/s41669-024-00556-w. Epub 2025 Jan 25.

"Towards harmonizing assessment and reimbursement of digital medical devices in the EU through mutual learning".通过相互学习促进欧盟数字医疗设备评估与报销的协调统一

NPJ Digit Med. 2024 Oct 1;7(1):268. doi: 10.1038/s41746-024-01263-w.

Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.跨国合作中的机遇与挑战：比荷卢经济联盟倡议的见解

J Mark Access Health Policy. 2024 Jul 9;12(3):144-157. doi: 10.3390/jmahp12030012. eCollection 2024 Sep.

本文引用的文献

Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.医疗器械的证据开发计划的覆盖范围在欧洲：特点和挑战。

Eur J Health Econ. 2021 Nov;22(8):1253-1273. doi: 10.1007/s10198-021-01334-9. Epub 2021 Jun 12.

Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal.现有的真实世界数据源能否为欧洲医疗器械的 HTA 提供合适的证据？映射和批判性评价。

Int J Technol Assess Health Care. 2021 Apr 26;37(1):e62. doi: 10.1017/S0266462321000301.

Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches.是否需要为罕见病治疗提供补充评估/报销流程？对国家方法的国际比较。

Orphanet J Rare Dis. 2020 Jul 20;15(1):189. doi: 10.1186/s13023-020-01462-0.

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.应用一般经济评价参考病例分析基因治疗的考虑因素。

Value Health. 2019 Jun;22(6):661-668. doi: 10.1016/j.jval.2019.03.012. Epub 2019 May 17.

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.是时候审视替代终点在卫生政策中的作用了：现状与未来方向。

Value Health. 2017 Mar;20(3):487-495. doi: 10.1016/j.jval.2016.10.011. Epub 2016 Dec 22.

Challenges in the Assessment of Medical Devices: The MedtecHTA Project.医疗器械评估中的挑战：MedtecHTA项目

Health Econ. 2017 Feb;26 Suppl 1:5-12. doi: 10.1002/hec.3469.

Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.替代终点在医疗政策中的应用：采用验证框架的建议

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.81. Epub 2016 Jun 3.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验